Brief: Omega Therapeutics Reports Preclinical Data Showing The Potential Of Omega Epigenomic Controllers To Synergize With Immunotherapies
31/05/2023 12:09
May 31 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS PRESENTS NEW PRECLINICAL DATA
DEMONSTRATING
THE POTENTIAL OF OMEGA EPIGENOMIC CONTROLLERS™ TO SYNERGIZE WITH
IMMUNOTHERAPIES AT THE ASCO 2023 ANNUAL MEETING
Source text for Eikon: ID:nGNX9QzdMx
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence